These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30380309)

  • 21. Improving Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer by adding interleukin 2 (IL-2): a mathematical model.
    Bunimovich-Mendrazitsky S; Halachmi S; Kronik N
    Math Med Biol; 2016 Jun; 33(2):159-88. PubMed ID: 25888550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Equilibrium solutions for microscopic stochastic systems in population dynamics.
    Lachowicz M; Ryabukha T
    Math Biosci Eng; 2013 Jun; 10(3):777-86. PubMed ID: 23906149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppression mediated by tumor cells: a challenge for immunotherapeutic approaches.
    Paillard F
    Hum Gene Ther; 2000 Mar; 11(5):657-8. PubMed ID: 10757345
    [No Abstract]   [Full Text] [Related]  

  • 24. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells.
    Poggi A; Musso A; Dapino I; Zocchi MR
    Immunol Lett; 2014; 159(1-2):55-72. PubMed ID: 24657523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multifaceted kinetics of immuno-evasion from tumor dormancy.
    d'Onofrio A
    Adv Exp Med Biol; 2013; 734():111-43. PubMed ID: 23143978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gompertz model with delays and treatment: mathematical analysis.
    Bodnar M; Piotrowska MJ; Foryś U
    Math Biosci Eng; 2013 Jun; 10(3):551-63. PubMed ID: 23906135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asymptotic dynamics of some t-periodic one-dimensional model with application to prostate cancer immunotherapy.
    Foryś U; Bodnar M; Kogan Y
    J Math Biol; 2016 Oct; 73(4):867-83. PubMed ID: 26897354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer.
    Bunimovich-Mendrazitsky S; Claude Gluckman J; Chaskalovic J
    J Theor Biol; 2011 May; 277(1):27-40. PubMed ID: 21334346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How do tumors actively escape from host immunosurveillance?
    Wilczyński JR; Duechler M
    Arch Immunol Ther Exp (Warsz); 2010 Dec; 58(6):435-48. PubMed ID: 20922572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal control problems with time delays: Two case studies in biomedicine.
    Göllmann L; Maurer H
    Math Biosci Eng; 2018 Oct; 15(5):1137-1154. PubMed ID: 30380303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico tumor control induced via alternating immunostimulating and immunosuppressive phases.
    Reppas AI; Alfonso JC; Hatzikirou H
    Virulence; 2016; 7(2):174-86. PubMed ID: 26305801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A model of the effects of cancer cell motility and cellular adhesion properties on tumour-immune dynamics.
    Frascoli F; Flood E; Kim PS
    Math Med Biol; 2017 Jun; 34(2):215-240. PubMed ID: 27094601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent progress in therapeutic antibodies for cancer immunotherapy.
    Lee A; Sun S; Sandler A; Hoang T
    Curr Opin Chem Biol; 2018 Jun; 44():56-65. PubMed ID: 29885949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "Tumor immunology meets oncology (TIMO) XII", April 28th-30th 2016, Halle/Saale, Germany.
    Seliger B
    Cancer Immunol Immunother; 2017 Nov; 66(11):1497-1503. PubMed ID: 28695228
    [No Abstract]   [Full Text] [Related]  

  • 35. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
    Lissoni P; Brivio F; Viviani S; Fumagalli L
    J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of mathematical models of cancer-immune interactions in the context of tumor dormancy.
    Wilkie KP
    Adv Exp Med Biol; 2013; 734():201-34. PubMed ID: 23143981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immuno-oncology-101: overview of major concepts and translational perspectives.
    Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tapping our immune potential to realise the ultimate goal.
    The Lancet Oncology
    Lancet Oncol; 2011 Dec; 12(13):1175. PubMed ID: 22123589
    [No Abstract]   [Full Text] [Related]  

  • 39. Optimal therapeutic protocols in cancer immunotherapy.
    Ghaffari A; Naserifar N
    Comput Biol Med; 2010 Mar; 40(3):261-70. PubMed ID: 20045103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunomodulation in cancer.
    Hegmans JP; Aerts JG
    Curr Opin Pharmacol; 2014 Aug; 17():17-21. PubMed ID: 25011112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.